Funding

SECTION I: ESTIMATION OF COSTS

1 Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result.
In this section we expect an analysis of funding needed or expected for valorization of the R&D result. An estimation is expected (range of costs not obviously exact amounts)
… in terms of IPR protection
No costs related to IPR protection are expected.

 

 

 

…in terms of product development
2 persons on software development for 1 year

 

…in terms of mass production
The production of modules in the OrganiK solution can follow the demand for such solutions. Therefore, the notion of ‘mass production’ does not apply here.

 

 

 

 

… in terms of marketing
2 persons active in sales/marketing for 1 year

 

 

 

 

2 Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs
  Year 1 Year 2 Year 3 Year 4 Year 5
Fixed costs 3.000 3.000 3.000 3.000 3.000
Personnel 100.000 120.000 180.000 240.000 280.000
           
Marketing costs 10.000 15.000 10.000 20.000 8.000
TOTAL EXPECTED COSTS 113.000 138.000 193.000 263.000 291.000
Price per Unit 5.000 10.000 12.000 8.000 4.000
Type of Unit OrganiK deployments/licenses
Number of Units 10 25 50 60 40
TOTAL Expected Revenues 50.000 250.000 600.000 480000 160000
CASH FLOW REQUIRED (REVENUES-COSTS) -63.000 112.000 407.000 217.000 -131.000
TOTAL CAPITAL required for five years 998.000

 

 

SECTION 2: QUALITATIVE FACTORS

4 Dimension of identified target groups
An estimation of the proportion of the target market (described in Section 3) which we expect to take
Due to the market’s sheer volume (e.g. 4,6B dollars), OrganiK is estimated to get a very small proportion of that size.

 

 

 

6 Evaluation of financial Risks for R&D result
OrganiK faces the usual financial risks as any start-up company: lower than expected market demand, higher than expected development/marketing costs, new competitors, etc.

 

 

 

 

SECTION 3: IDENTIFICATION OF FINANCING SOURCES

After evaluating all the above mentioned criteria, please tick the best financing source for the achievement of R&D result (i.e. own capitals, banking credits, venture capital, business angels, etc)

1. European Funding

Define relevance of the product with the following potential funding sources and comment

Note: INTERVALUE partners are expected to pre-define a list of existing European funding sources for product development available for the country and advisors will check whether the proposed product is relevant for that funding source or may define an additional source
1. VCs

2. Seed capital/ Business angels

3. European Investment Bank

4. European Research Projects

2 National Funding
Note: INTERVALUE partners are expected to pre-define a list of existing national funding sources for product development available for the country and advisors will check whether the proposed product is relevant for that funding source or may define an additional source
1. VCs

2. National Banks

3. Greek Framework Programmes

3 Private funding
Note: INTERVALUE partners are expected to pre-define a list of existing private funding sources for product development available for the country and advisors will check whether the proposed product is relevant for that funding source or may define an additional source
1. VCs

2. Seed capital/ Business angels

3. National and/or European Banks

4 Other

SECTION 3: FINAL EVALUATION

It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)…
OrganiK can be a promising spin-off and belongs in a high-growth business sector (Enterprise Social Software). Since the technology is mature enough the endeavor can start with a minimum of resources and therefore risk. The modular capability of the platform which can be connected to pricing models offers the opportunity of a gradual commercial exploitation approach.

 

 

Decision of evaluation (Please tick  as appropriate)

The R&D has a high potential of exploitation
  The R&D result needs minor revisions
  The R&D result needs moderate revisions
  The R&D result needs major revisions
  The R&D result has no potential of exploitation

Bookmark the permalink. Follow any comments here with the RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

Post a Comment

You must be logged in to post a comment.

Request a proposal

Valorisation Plan Authors

Related Documents

There in no related documents

Visit the other applications of the INTERVALUE Platform: R&D Repository | IP Agreements

© 2009-2010 INTERVALUE Project